Inflarx Surges 24.66% on Phase II Success, Partners, & Regulatory Boost
Inflarx surges 24.7% in just 24 hours, driven by Phase II success, new CRO partnership, and favorable EU regulation, positioning it for next‑generation monoclonal antibodies.
4 minutes to read